Heron Therapeutics, Inc. Earnings Recaps
Q2 2026
Aug 12, 2026
Heron Therapeutics’ shares plunged 34% following Q2 results as revenue growth fell short of expectations and management cut guidance amid heightened competition and patent uncertainties, signaling investor disappointment with the company’s cautious outlook and margin pressures.
Key takeaways
- Total net revenue came in at $37.7 million, up sequentially but below company internal plans.
- ZYNRELEF grew 35% year-over-year with 19% growth in average daily units but adoption pace was slower than anticipated.
- APONVIE sales increased 74% year-over-year, reaching a 23% share of the surgical NK-1 segment, though still early in the adoption curve.
- CINVANTI revenue rose to $21.8 million from $20.5 million sequentially but was down about 10% year-over-year due to branded competition and patent litigation headwinds.
- Company halted sales force expansion and tightened spending following a court decision affecting CINVANTI patents; preparing for potential generic entry while considering strategic alternatives.
Q1 2026
May 12, 2026
Shares of Heron Therapeutics plunged 20.3% following earnings, reflecting investor disappointment with a pronounced Q1 sales deceleration driven by severe weather disruptions and cautious near-term outlook despite solid underlying fundamentals.
Key takeaways
- Total net sales in Q1 2026 came in at $34.7 million, hampered by severe weather causing the most difficult month for elective surgeries since the CEO’s tenure began.
- Acute Care portfolio grew 32% YoY, with ZYNRELEF up 27% and APONVIE soaring over 50%, supported by a successful IGNITE incentive program and new clinical guideline endorsements.
- Oncology sales remained stable but reflected normal quarter-to-quarter timing, with CINVANTI maintaining a 25% exit market share in its category amid increased competition.
- Management highlighted a seasonal headwind compounded by weather that depressed January demand but expects deferred procedures to reschedule later in the year, anticipating a strong H2 seasonal rebound.
- Execution on sales force expansion is on track for Q3, intended to drive growth, but the market reaction indicates skepticism about near-term growth prospects and margin sustainability.
Q3 2025
Nov 5, 2025
Heron Therapeutics reported a strong Q3 2025, generating net revenues of $38.2 million and achieving adjusted EBITDA of $1.5 million, highlighting significant growth in its acute care portfolio.
Key takeaways
- Achieved 49% year-over-year growth in ZYNRELEF net sales, reaching $9.3 million in Q3 2025.
- APONVIE sales surged 173% year-over-year, totaling $3 million, with a dedicated sales team now deployed.
- Implemented successful initiatives, including the CrossLink Ignite program and the introduction of a product-specific J-code for ZYNRELEF, enhancing distributor engagement and reimbursement processes.
- Continued strong performance in CINVANTI, maintaining steady demand despite competitive pressures.
- Year-to-date revenues of $114.3 million, with positive momentum projected to continue into Q4 and beyond.